- The vaccine, whose development took 12 years and was tested on apes, will help the immune system produce antibodies that act against the virus.
- The human study is scheduled for completion on June 23, 2023.
- Globally, it is estimated that there are 25 million transgender people with a 49-fold increased risk of living with HIV
A team of researchers said Monday that “no later than 2023” they will circulate the first vaccine against Human Immunodeficiency Virus (HIV), which will stop “at least 65%” the spread of the pandemic. They confirmed it in the framework of the 10th World Scientific Conference on HIV in Mexico. A human study will be carried out, involving 3,800 people and is estimated to begin in the coming months in the United States.
The announcement was made during the X Scientific Conference on HIV, which will end tomorrow in Mexico City and with the participation of more than 6,000 specialists worldwide. According to doctors, the vaccine, whose development took 12 years and was tested on apes, will help the immune system produce antibodies that act against the virus.
The human study is scheduled for completion on June 23, 2023. Participants, who will be “men who have sex with men” and “transgender people” and will be offered in about 55 clinical research centers in nine countries. Participants will receive vaccines at four-time points for a year and will be randomized to receive the regimen of experimental vaccine or placebo.
“The study will evaluate the efficacy of a vaccine that, in the preliminary stages, showed promising results. Until now, previous attempts have failed, but the design of this project, called Mosaic, allows cautious optimism,” said Pedro Cahn, Scientist Director, Guest Foundation. Cahn, who is in Mexico participating in the international scientific conference, said that Guest Foundation “is very committed to the initiative.” “This can generate a turning point in the history of the epidemic,” the expert hoped.
Globally, it is estimated that there are 25 million transgender people with a 49-fold increased risk of living with HIV, while men who have sex with men represent 66% of new infections with that virus in the United States and a large proportion of new infections in North and South America, as well as in some parts of Europe.
“We are determined to develop an effective HIV vaccine worldwide to reduce the trajectory of the estimated 1.5 million new infections that are occurring each year,” Larry Corey added., principal investigator of the Mosaic study, virologist and member of Fred Hutchinson Cancer Research Center, in Seattle.
The specialist said that the vaccine “will be another tool that will prevent HIV, but it will not replace other methods. “The study and development of the vaccine is sponsored by a laboratory in the United States, and although it is expected that in four years there will be clear results on its effectiveness, it is not yet known when it will be available to the general public. According to the latest report published by the UN, the rate of HIV- infected in Latin America grew by 7% between 2010 and 2018, a fact that places the region between the “areas to be monitored” in the fight against the virus.